Seribantumab Completed Phase 2 Trials for Her2 Negative Breast Cancer Patients Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01151046Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer